<DOC>
	<DOCNO>NCT01884285</DOCNO>
	<brief_summary>This phase I , open-label , multicentre study AZD8186 administer orally patient advance castrate-resistant prostate cancer ( CRPC ) , squamous non-small cell lung cancer ( sqNSCLC ) , triple negative breast cancer ( TNBC ) know PTEN-deficient/mutated PIK3CB mutated/amplified advanced solid malignancy monotherapy combination abiraterone acetate AZD2014 .</brief_summary>
	<brief_title>AZD8186 First Time In Patient Ascending Dose Study</brief_title>
	<detailed_description>This phase I , open-label , multicentre study AZD8186 administer orally patient advance castrate-resistant prostate cancer ( CRPC ) , squamous non-small cell lung cancer ( sqNSCLC ) , triple negative breast cancer ( TNBC ) know PTEN-deficient/mutated PIK3CB mutated/amplified advanced solid malignancy . The study design allow escalation dose intensive safety monitoring ensure safety patient . There 4 part study : Part A , monotherapy dose escalation , Part B , monotherapy expansion cohort ( ) PTEN deficient patient monotherapy intend therapeutic dose ( ) schedule ( ) , Part C , AZD8186 add abiraterone accetate ( prednisone ) treatment - dose/ schedule find followed expansion phase PTEN-deficient/mutated PIK3CB mutate mCRPC Part D , AZD8186 combination AZD2014 ( novel dual mTORC1/2 inibitor ) dose/schedule find followed expansion phase PTEN-deficient/mutated PIK3CB mutate TNBC .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Abiraterone Acetate</mesh_term>
	<criteria>Provision sign date , write informed consent prior study specific procedure Male female , age 18 year old Histologically cytologically proven diagnosis prostate cancer , sqNSCLC , TNBC , know PTENdeficient solid malignancy , refractory standard therapy . Females use adequate contraceptive measure , breast feeding must negative pregnancy test prior start dose childbearing potential WHO/ECOG performance status 0 1 deterioration previous 2 week min life expectancy 12 week Tumours know genomic alteration PTEN PIK3CB local test result may also eligible . Part B Tumour amenable take paired biopsy opinion investigator.Patients TNBC mCRPC : PTENdeficient tumour Parts A , B D1 ( mCRPC ) PSA screen must ≥2 µg/L . Preceding line treatment include response antiandrogen , progression document withdrawal antiandrogen . Serum testosterone concentration ≤50 ng/dL sustain medical surgical castration Parts A , B D ( TNBC ) Oestrogen receptor , progesterone receptor HER2 negative advance adenocarcinoma breast . Parts A , B D1 ( solid malignancy ) Consented provision formalin fix paraffin embed blocks/ slide recent tissue sample . Part C ( patient ) : May receive treatment abiraterone acetate , enzalutamide and/or one prior chemotherapy ( docetaxel ) Serum testosterone concentration ≤50 ng/dL sustain medical surgical castration . Early confirm evidence progressive disease . Last PSA value increase ≥ 25 % first PSA value absolute increase ≥2 ng/mL first PSA value Serum potassium &gt; 3.5 mmol/L Parts C2 D2 Prospectively determine eligible PTEN alteration determine next generation sequencing , protein deficient determine IHC PIK3CB mutation/amplification . Part D2 Measurable disease ( least 1 lesion ≥10 mm long diameter lymph node short axis ≥15 mm ) CT/MRI Exclusion Criteria Treatment study 1 . Nitrosourea mitomycin C within 6 week 2 . Investigational agent previous clinical study within 4 week 3 . Chemotherapy , immunotherapy anticancer agent within 4 week 4. hormonal therapy Treatment study 1 . Strong inhibitor strong moderate inducer CYP3A4 2 . Radiotherapy wide field radiation within 4 week , With exception alopecia toxicity relate use gonadotropinreleasing hormone agonist unresolved toxicity prior therapy great CTCAE grade 1 time study treatment Spinal cord compression brain metastasis unless asymptomatic treat stable require steroid Evidence severe uncontrolled systemic disease include active liver disease ( malignancy ) , active bleeding diatheses , active infection include hepatitis B , hepatitis C human immunodeficiency virus ( HIV ) . Exclusion crtieria Part C Preexisting Grade 2 high chronic diarrhoea Major bowel surgery opinion Investigator exclude patient Use antibiotic treat chronic infection within 28 day prior first dose Sensitive narrow therapeutic range substrate CYP2D6 Severe moderate hepatic impairment Persistent uncontrolled hypertension ( systolic &gt; 160 mmHg/ diastolic &gt; 100 mmHg Exclusion Criteria Part D Exposure potent moderate inhibitor inducer CYP3A4/5 CYP2C8 take within state washout period first dose Exposure sensitive narrow therapeutic range substrate drug metabolise enzyme CYP2C8 , CYP2C9 , CYP2C19 drug transporter Pgp , BCRP , OATP1B1 , OATP1B3 , OCT1 OCT2 within appropriate washout period first dose study treatment . Haemopoietic growth factor within 2 week prior receive study drug . Patients experience follow procedure condition currently precede 12 month : coronary artery bypass graft , vascular stent , myocardial infarction , angina pectoris , congestive heart failure New York Heart Association Grade ≥2 , supraventricular arrhythmia include atrial fibrillation , uncontrolled , haemorrhagic thrombotic stroke , include transient ischaemic attack central nervous system bleed . Abnormal ECHO MUGA baseline &lt; 55 % . Patients Diabetes Type I uncontrolled Type II judge Investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Advanced Castrate-resistant Prostate Cancer ( CRPC )</keyword>
	<keyword>Squamous Non-Small Cell Lung Cancer ( sqNSCLC )</keyword>
	<keyword>Triple Negative Breast Cancer ( TNBC )</keyword>
	<keyword>PTEN-deficient/mutated Advanced Solid Malignancies</keyword>
	<keyword>PIK3CB mutated/amplified advanced solid malignancy</keyword>
</DOC>